PE20091560A1 - ORAL DISINTEGRATION TABLET - Google Patents

ORAL DISINTEGRATION TABLET

Info

Publication number
PE20091560A1
PE20091560A1 PE2009000311A PE2009000311A PE20091560A1 PE 20091560 A1 PE20091560 A1 PE 20091560A1 PE 2009000311 A PE2009000311 A PE 2009000311A PE 2009000311 A PE2009000311 A PE 2009000311A PE 20091560 A1 PE20091560 A1 PE 20091560A1
Authority
PE
Peru
Prior art keywords
found
weight
parts
dispersion
disintegration tablet
Prior art date
Application number
PE2009000311A
Other languages
Spanish (es)
Inventor
Hidekazu Okazaki
Naoki Kamada
Masafumi Toda
Tadashi Fukami
Haruka Koizumi
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of PE20091560A1 publication Critical patent/PE20091560A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA EN FORMA DE COMPRIMIDO DESINTEGRANTE ORAL, QUE COMPRENDE: A) CILOSTAZOL Y SACARIDOS TALES COMO MANITOL, XILITOL, ENTRE OTROS EN FORMA DE PARTICULAS GRANULADAS QUE SE PREPARAN POR DISPERSION UNIFORME DE UNA SUSTANCIA INORGANICA Y UN AGENTE DESINTEGRANTE, DONDE (a) LOS SACARIDOS SE ENCUENTRA EN 40-90 PARTES EN PESO, (b) LA SUSTANCIA INORGANICA SE ENCUENTRA EN 1-30 PARTES EN PESO Y (c) EL AGENTE DESINTEGRANTES SE ENCUENTRA EN 5-40 PARTES EN PESO; B) UN DESLIZANTE TAL COMO DIOXIDO DE SILICIO HIDRATADO, ACIDO SILICICO ANHIDRO LIVIANO Y PESADO, QUE SE ENCUENTRA EN UNA CANTIDAD DE 0.2% A 2% (p/p); C) UN EXCIPIENTE ORGANICO TALES COMO ALMIDON DE MAIZ, CELULOSA CRISTALINA, ENTRE OTROS; D) UNO O MAS ADITIVOS OPCIONALES TALES COMO LUBRICANTES, EDULCORANTES, AROMATIZANTES, ENTRE OTROS. DICHO COMPRIMIDO ES UTIL PARA PACIENTES DE EDAD AVANZADA Y PACIENTES QUE SUFREN DE DISFAGIAIT REFERS TO A PHARMACEUTICAL COMPOSITION IN THE FORM OF AN ORAL DISINTEGRANT TABLET, WHICH INCLUDES: A) CILOSTAZOL AND SACCHARIDS SUCH AS MANNITOL, XYLITOL, AMONG OTHERS IN THE FORM OF GRANULATED PARTICLES THAT ARE PREPARED BY A UNIQUE DISPERSION, A UNDEFINANT DISPERSION AND INTO A SUBSTANT DISPERSION. (a) THE SACCHARDS IS FOUND IN 40-90 PARTS BY WEIGHT, (b) THE INORGANIC SUBSTANCE IS FOUND IN 1-30 PARTS BY WEIGHT AND (c) THE DISINTEGRANT AGENT IS FOUND IN 5-40 PARTS BY WEIGHT; B) A SLIPPER SUCH AS HYDRAATED SILICON DIOXIDE, LIGHT AND HEAVY ANHYDROUS SILICONE ACID, WHICH IS IN A QUANTITY OF 0.2% TO 2% (p / p); C) AN ORGANIC EXCIPIENT SUCH AS CORN STARCH, CRYSTALINE CELLULOSE, AMONG OTHERS; D) ONE OR MORE OPTIONAL ADDITIVES SUCH AS LUBRICANTS, SWEETENERS, AROMATIZERS, AMONG OTHERS. SAID COMPRESSED IS USEFUL FOR OLDER PATIENTS AND PATIENTS SUFFERING FROM DYSPHAGIA

PE2009000311A 2008-02-29 2009-02-27 ORAL DISINTEGRATION TABLET PE20091560A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008050460 2008-02-29

Publications (1)

Publication Number Publication Date
PE20091560A1 true PE20091560A1 (en) 2009-10-30

Family

ID=40718911

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000311A PE20091560A1 (en) 2008-02-29 2009-02-27 ORAL DISINTEGRATION TABLET

Country Status (7)

Country Link
EP (1) EP2262487A2 (en)
JP (1) JP2011513194A (en)
AR (1) AR070530A1 (en)
CL (1) CL2009000452A1 (en)
PE (1) PE20091560A1 (en)
TW (1) TW200936184A (en)
WO (1) WO2009107864A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8779146B2 (en) 2010-04-28 2014-07-15 Nuformix Limited Cilostazol cocrystals and compositions
ES2422657B1 (en) * 2012-02-10 2014-06-11 Laboratorios Normon S.A. Cilostazol solid pharmaceutical composition
US9988542B2 (en) 2012-07-20 2018-06-05 Otsuka Pharmaceutical Co., Ltd. Tablet having dry-ink film on surface thereof, and ink for inkjet printer
JP5713421B1 (en) 2013-07-19 2015-05-07 株式会社三和化学研究所 Orally disintegrating tablets
US9974738B2 (en) 2013-09-27 2018-05-22 Daicel Corporation Disintegrating particle composition produced by two-stage wet granulation process, and intraorally disintegrating tablet containing same composition
US10231914B2 (en) * 2015-06-02 2019-03-19 Lynette Batton Effervescent tablet for elimination of red wine discoloration, offensive odour of mouth and cleaning the palate
EP3409294A1 (en) 2017-06-01 2018-12-05 Przedsiebiorstwo Farmaceutyczne Lek-Am Sp Z O. O. Tablets containing cilostazol of specific particle size distribution

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
AU2001248751A1 (en) * 2000-04-12 2001-10-23 Banyu Pharmaceutical Co. Ltd. Compositions disintegrating in oral cavity and preparations disintegrating in oral cavity
JP4637338B2 (en) * 2000-09-22 2011-02-23 大塚製薬株式会社 Cilostazol dry coated tablets
JP4551627B2 (en) * 2003-02-28 2010-09-29 東和薬品株式会社 Method for producing orally disintegrating tablets
JP3841804B2 (en) * 2003-10-15 2006-11-08 富士化学工業株式会社 Composition for intraorally rapidly disintegrating tablets
KR101159617B1 (en) * 2003-10-15 2012-06-27 후지카가쿠고교가부시키가이샤 Tablet quickly disintegrating in oral cavity
TWI383809B (en) * 2005-06-29 2013-02-01 Otsuka Pharma Co Ltd Orally disintegrating powder comprising cilostazol
JP5074190B2 (en) * 2005-09-02 2012-11-14 富士化学工業株式会社 Orally rapidly disintegrating tablets

Also Published As

Publication number Publication date
TW200936184A (en) 2009-09-01
JP2011513194A (en) 2011-04-28
WO2009107864A2 (en) 2009-09-03
AR070530A1 (en) 2010-04-14
CL2009000452A1 (en) 2010-03-26
EP2262487A2 (en) 2010-12-22
WO2009107864A3 (en) 2009-12-03

Similar Documents

Publication Publication Date Title
PE20091560A1 (en) ORAL DISINTEGRATION TABLET
PE20142305A1 (en) N-ARYLTHRIAZOLE COMPOUNDS AS LPAR ANTAGONISTS
PE20142440A1 (en) IMMEDIATE RELEASE ORAL PHARMACEUTICAL COMPOSITIONS WITH NON-ENTERIC COATING INCLUDING 5-AZACITIDINE
CL2012003211A1 (en) Compounds derived from piperidinyl substituted lactams, modulators of gpr119; process to prepare the compounds; pharmaceutical composition comprising the compounds; and use of the compounds in the preparation of medicaments for the treatment or prevention of type 2 diabetes, obesity and related conditions
EA201290394A1 (en) MORPHOLINOTHASOLES AS POSITIVE ALLOSTERIC ALPHA MODULATORS 7
CL2011003072A1 (en) Compounds derived from 4'- (isoxazol-5-yl) -biphenyl-4-yl-cycloalkyl (c3-8), antagonists of the lysophosphatidic acid receptor; pharmaceutical composition comprising them; and its uses in the treatment of cancer, lung problems, among others.
PE20090185A1 (en) PHARMACEUTICAL FORMULATIONS CONTAINING AN SGLT2 INHIBITOR
AR094548A1 (en) PHYSICALLY STABLE SOLID DISPERSION
PE20100050A1 (en) PHARMACEUTICAL DOSAGE FORM FOR IMMEDIATE RELEASE OF AN INDOLINONE DERIVATIVE
EA201390332A1 (en) DEUDIED PRIDOPIDINE ANALOGUES APPLICABLE AS DOPAMINER STABILIZERS
EA201071288A1 (en) TRIPLE PYRAZOLES AS MODULATORS OF ACETYLCHOLINE RECEPTORS
UA104869C2 (en) Normal;heading 1;heading 2;heading 3;PHARMACEUTICAL FORMULATIONS CONTAINING DOPAMINE RECEPTOR LIGANDS
PE20130481A1 (en) PHARMACEUTICAL COMPOSITIONS INCLUDING 4-AMINO-5-FLUORO-3- [6- (4-METHYL-PIPERAZIN-1-IL) -1H-BENZYMIDAZOL-2-IL] -1H-QUINOLIN-2-ONA LACTATE MONOHYDRATE
CU24619B1 (en) AMORPHOUS LETERMOVIR AND SOLID PHARMACEUTICAL FORMULATIONS THEREOF FOR ORAL ADMINISTRATION
EA201300539A1 (en) HARDWARE
DOP2010000232A (en) INDAZOL DERIVATIVES
CO6630178A2 (en) New low concentration meloxicam tablets
EA201500375A1 (en) COMPOSITION FOR CARE OF THE ORAL CAVITY
TN2015000135A1 (en) Modified release formulations for oprozomib
AR061790A1 (en) SOLID PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION, FORMULATIONS OF IMMEDIATE RELEASE TABLETS OF A THROMBIN RECEIVER ANTAGONIST, AND ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT
EA201171399A1 (en) METHOD AND COMPOSITION FOR IMPROVING SUCTION OF MEDICINES
MX344846B (en) Combination of active loaded granules with additional actives.
UA112352C2 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF MENTAL, BEHAVIOR, AND COGNITIVE DISORDERS
PE20080673A1 (en) RAPID DISINTEGRATION FREEZE DRIED ORAL FORMULATIONS OF A THROMBIN RECEPTOR ANTAGONIST
AR094146A1 (en) SOLID UNIT WITH HIGH CONTENT IN FEXOFENADINE AND ITS PREPARATION PROCEDURE

Legal Events

Date Code Title Description
FD Application declared void or lapsed